BMY

Bristol-Myers Squibb Company is a global biopharmaceutical company discovering, developing, manufacturing, and marketing prescription medicines for serious diseases including cancer, cardiovascular conditions, immunology disorders, and fibrosis. The company's portfolio includes leading oncology brands such as Opdivo, Yervoy, and Revlimid, cardiovascular medicines including Eliquis, and emerging franchises in immunology. Bristol-Myers Squibb was formed through the 2019 merger of Bristol-Myers Squibb and Celgene Corporation, combining two major pharmaceutical companies to create a leading oncology and immunology powerhouse. The company invests heavily in research and development, clinical trials, and business development to maintain a robust pipeline. Headquartered in New York City with major operations in New Jersey, Bristol-Myers Squibb serves patients and healthcare providers globally through direct sales, distributors, and partnerships. The company faces significant patent expirations including the loss of Revlimid exclusivity, requiring successful new product launches to offset revenue declines. Bristol-Myers Squibb benefits from strong oncology and cardiovascular franchises and advancing pipeline programs. The company continues to invest in innovative therapies and strategic acquisitions to drive long-term growth.